| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3979421 | Bulletin du Cancer | 2010 | 9 Pages |
Abstract
We propose here a general review of current questions related to early trials, including the choice of the primary endpoint, role of bayesian designs, role of stratification and randomization for phase 2 trials, patient selection, and new designs for phase 1 and phase 0 trials. We also discuss the difficulties to apply such methodologies to molecular targeted therapies development.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
N. Penel, C. Fournier, C. Stéphanie,